12:00 AM
 | 
Jan 12, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CMX001: Phase I data

In a double-blind, placebo-controlled Phase I trial in 84 healthy volunteers, oral CMX001 was well tolerated...

Read the full 59 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >